Latest News

Latest News

Join The Future Of Life Sciences Media

 

In a world overflowing with information, LifeScienceDaily.news stands apart as the dedicated space where life sciences professionals share what’s new, what’s next, and why it matters, all in real time.

 

 

Don’t wait for the media to pick up your story. Be the media.

More News

Compliant on Paper, Exposed in Practice

Compliant on Paper, Exposed in Practice

A pharmaceutical manufacturer completes a technology transfer. The validation protocols have been approved. Training records are complete, documentation has been reviewed, and every required signature has been collected. The project passes its milestones and moves...

read more
From Reactive Reviews to Predictive Regulatory Intelligence

From Reactive Reviews to Predictive Regulatory Intelligence

Every regulatory professional has experienced the same moment. After months, and sometimes years, of preparing a Chemistry, Manufacturing, and Controls (CMC) submission, the application is finally submitted to a health authority. At that point, the questions begin....

read more
The Patient as Healthcare’s Systems Integrator

The Patient as Healthcare’s Systems Integrator

Healthcare has undergone a remarkable digital transformation over the past two decades. Electronic health records, electronic prescribing, patient portals, telemedicine, artificial intelligence, and remote monitoring have fundamentally changed how healthcare is...

read more
Weekly News Roundup | 20 July 2026

Weekly News Roundup | 20 July 2026

Life science news 20 July 2026: the FDA approves the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly makes the largest psychedelics deal in Big Pharma history, and a first-in-class breast cancer therapy wins regulatory clearance in a landmark week for...

read more
NAMs and Animal Testing: Separating Progress From Hype

NAMs and Animal Testing: Separating Progress From Hype

If you followed the headlines over the past two years, you could be forgiven for thinking animal testing in drug development is already on its way out. In December 2022, the FDA Modernization Act 2.0 removed the blanket legal requirement for animal studies to support...

read more
Clinical Trials Roundup | 17 July 2026

Clinical Trials Roundup | 17 July 2026

Celcuity's gedatolisib receives FDA approval as the first pan-PI3K and mTOR inhibitor for advanced breast cancer, Biogen's diranersen delivers detailed Phase 2 CELIA data showing tau reduction and cognitive benefit in early Alzheimer's disease, Novo Nordisk's...

read more
Compliant on Paper, Exposed in Practice

Compliant on Paper, Exposed in Practice

A pharmaceutical manufacturer completes a technology transfer. The validation protocols have been approved. Training records are complete, documentation has been reviewed, and every required signature has been collected. The project passes its milestones and moves...

read more
From Reactive Reviews to Predictive Regulatory Intelligence

From Reactive Reviews to Predictive Regulatory Intelligence

Every regulatory professional has experienced the same moment. After months, and sometimes years, of preparing a Chemistry, Manufacturing, and Controls (CMC) submission, the application is finally submitted to a health authority. At that point, the questions begin....

read more
The Patient as Healthcare’s Systems Integrator

The Patient as Healthcare’s Systems Integrator

Healthcare has undergone a remarkable digital transformation over the past two decades. Electronic health records, electronic prescribing, patient portals, telemedicine, artificial intelligence, and remote monitoring have fundamentally changed how healthcare is...

read more
Weekly News Roundup | 20 July 2026

Weekly News Roundup | 20 July 2026

Life science news 20 July 2026: the FDA approves the first oral PCSK9 inhibitor for high cholesterol, Eli Lilly makes the largest psychedelics deal in Big Pharma history, and a first-in-class breast cancer therapy wins regulatory clearance in a landmark week for...

read more
NAMs and Animal Testing: Separating Progress From Hype

NAMs and Animal Testing: Separating Progress From Hype

If you followed the headlines over the past two years, you could be forgiven for thinking animal testing in drug development is already on its way out. In December 2022, the FDA Modernization Act 2.0 removed the blanket legal requirement for animal studies to support...

read more
Clinical Trials Roundup | 17 July 2026

Clinical Trials Roundup | 17 July 2026

Celcuity's gedatolisib receives FDA approval as the first pan-PI3K and mTOR inhibitor for advanced breast cancer, Biogen's diranersen delivers detailed Phase 2 CELIA data showing tau reduction and cognitive benefit in early Alzheimer's disease, Novo Nordisk's...

read more

Featured Articles

DNA double helix beside a microscope, test tubes and a pipette over a petri dish, representing life science publishing

Life Science Publishing: Our First Year, and Where You Fit In

Almost a year ago, Life Science Daily News published its first articles with a simple belief. Specialist science deserves a specialist stage. Since then, that belief has grown into a global readership and an active community of contributors. This is the story of our...
FDA building exterior alongside pharmaceutical laboratory setting representing drug approval decisions

FDA Drug Approval Decisions

Last updated 28 October 2026. Covering target action dates from October 2026 to February 2027. October changed how this tracker has to be read. Six FDA drug approval decisions landed in the month, and four arrived ahead of target. One cleared roughly 12 weeks early,...
gloved hands holding a glowing blue sample vial (labelled LOT: 24-B1, SAMPLE: GENO-) with a lab researcher working in the background.

CRISPR Gene Editing 2026: Rare Diseases, Cancer and Autoimmune

CRISPR gene editing in 2026 is no longer a technology to watch. It is a technology delivering results. Across three distinct disease areas, rare inherited conditions, haematologic and solid cancers, and autoimmune disease, clinical programmes are accumulating...
Three GLP-1 drug pipeline injection pens and oral tablets beside a clinical trial efficacy chart on a clipboard

The GLP-1 Drug Pipeline: Every Candidate to Watch in 2026

The GLP-1 drug pipeline has become one of the most consequential and closely watched in modern pharmaceutical history. In 2026, the class of glucagon-like peptide-1 receptor agonists is no longer defined solely by Ozempic and Wegovy. A new generation of oral tablets,...
Sjögren's disease diagnosis: close-up of a dry, irritated eye with eye drops being applied

Anti-Ro52 vs Anti-Ro60: Advancing Sjögren’s Disease Diagnosis

Autoantibody testing is a central part of autoimmune disease diagnosis, including Sjögren’s disease (SjD). The American College of Rheumatology and European Alliance of Associations of Rheumatology (ACR/EULAR) classification criteria for SjD incorporate ocular and...

Further News

Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

Biopharma H1 2026 Review: Deals, Drugs, and Pipeline Shifts

The first half of 2026 delivered one of the most consequential periods in recent biopharma history, reshaping competitive landscapes through record dealmaking, landmark regulatory approvals, and pivotal clinical breakthroughs. This biopharma H1 2026 review examines...

read more
CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

CagriSema FDA Review: Novo Nordisk NDA Timeline Explained

The CagriSema FDA review has become one of the most closely watched regulatory processes in metabolic medicine. Novo Nordisk filed a New Drug Application for its once-weekly obesity combination in December 2025, and a decision is widely expected in the final quarter...

read more
The Evidence Gap in Precision Prevention

The Evidence Gap in Precision Prevention

Preventive medicine is entering a new era. Advances in genomics, biomarker testing, continuous monitoring technologies, imaging, and data analytics are enabling clinicians to identify disease risk with a level of precision that would have been unimaginable just a...

read more
Are Animal Models Limiting Progress in Product Development?

Are Animal Models Limiting Progress in Product Development?

While animal models have played a central role in safety assessment and biological research for decades, advances in cellular biology, computational modelling, and micro physiological systems are prompting scientists to explore new ways of generating human-relevant...

read more
The Infrastructure Gap Behind the GLP-1 Boom

The Infrastructure Gap Behind the GLP-1 Boom

The rapid rise of GLP-1 medications has transformed healthcare delivery in ways few therapeutic categories have achieved in recent decades. Originally developed to help manage type 2 diabetes, GLP-1 receptor agonists such as semaglutide and tirzepatide have become...

read more
How Climate Change is Redrawing Europe’s Disease Landscape

How Climate Change is Redrawing Europe’s Disease Landscape

The impact of climate change is usually discussed in terms of heatwaves and floods. While less visible, its impact on infectious diseases is equally consequential for public health.  New data from the UK Health Security Agency (UKHSA) showing a surge in chikungunya...

read more

Further News

Digital Health and the Reordering of Life Sciences Commercialization

It’s been an extraordinary two years for anyone working in pharma commercialization, with the macro environment shifting meaningfully under the feet of all those sitting on the commercial side of pharma or building in digital health with pharma partnership...

From Data to Decisions: The Next Frontier in Diabetic Foot Care

If you are not aware of the statistics on diabetic limb loss, they deserve your attention.  Prevention is an absolute necessity.  We call this diabetic foot care, and the way podiatrists utilize these opportunities is moving into a more data-rich era. Remote...

Expedited IND Pilot Opens as UK Fast Track Bars First-in-Human

The US Food and Drug Administration began accepting applications on 15 September 2026 for its expedited IND pilot. The programme is a key component of Operation TrialBlazer, according to the agency. The Department of Health and Human Services announced that initiative...

Why Pharmaceutical Quality Cannot Be Tested Into a Product

In pharmaceutical manufacturing, quality control testing is often the point at which a product gets its final analytical assessment. But from my experience in pharmaceutical quality control, one principle is worth emphasizing: QC testing is essential, but QC testing...

Fifty Patients, No Registry: MVA Research Meets in London

Mosaic variegated aneuploidy (MVA) is thought to affect fewer than 50 people worldwide. At that scale, ultra-rare disease research runs into a problem that funding alone does not solve. There is no cohort large enough to randomise. There is often no natural history...

Semaglutide Patent Expiry: What Generics Did to Prices

The semaglutide patent expiry of March 2026 has now had six months to work. The evidence is uneven. In India, prices fell by up to 70% within weeks. In Canada, generic pens reached pharmacies in May. In China, not one generic has been approved. Readers in the United...

AI as a Research Partner for the Overstretched Life Sciences

Generative AI can lift the administrative weight of literature reviews and manuscript drafting, but only when it stays grounded in evidence and firmly under human control. The problem we know too well Every clinician who also publishes lives with a quiet collision. On...

FDA Clears First Glioma PET Imaging Drug After 2025 Rejection

The FDA has approved Pixclara, the first glioma PET imaging drug, sixteen months after rejecting the same application. No UK filing has been announced.

    Medical AI Is Getting Better. Why Is Diagnosis Getting Harder?

    A radiologic study today rarely arrives alone. It comes wrapped in automated detection flags, quantitative lesion scores, an AI-drafted report, historical imaging, EHR clinical notes, and subspecialty consult requests. What it does not come wrapped in is medical AI...

    Stellaromics Expands Pyxa Adoption Across the U.S. and Europe

    Stellaromics Expands Pyxa® Adoption as Instruments are Installed at Leading Research Institutions Across the U.S. and Europe Icahn School of Medicine at Mount Sinai, CNAG, Karolinska Institutet, and Stanford University will apply 3D spatial multi-omics across...

    Freeze-Dried Does Not Mean Pathogen-Free

    Once concentrated in commercial manufacturing, freeze-drying has entered home kitchens and small food businesses through countertop equipment. That shift has made freeze-dried food safety a live question for small operators. University of Minnesota Extension describes...

    Why AI Governance in Life Sciences Can’t Wait for Regulatory Clarity

    The regulatory picture for AI governance in life sciences just got more confusing, not less. In June 2026, the European Union's Digital Omnibus package pushed back the EU AI Act's compliance deadline for stand-alone high-risk AI systems from August 2026 to December...

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.

    See More Articles

    Want to Be Part of the Next Chapter in Life Sciences Media?

     

    LifeScienceDaily.news is building a new kind of platform where innovators, researchers, and industry leaders tell their own stories and shape the narrative of what’s next in life sciences. Share your story and lead the conversation.

     

     

    Don’t wait for the media to pick up your story. Be the media.